Search

everythinglearnresearchcommunity

for

Search:↓

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The user experienced increased hair shedding after one month on 0.25 mg finasteride, despite initial improvement. This shedding may be a normal phase in the hair cycle and could improve in the coming months.

User reports using 1.25 mg oral finasteride each morning and 0.75 ml minoxidil topical spray twice a day, along with vitamin D pills. Another user comments on the positive results and asks when finasteride stabilized shedding.

A user shared their 6.5-month experience with topical finasteride (2%) and minoxidil (5%), noting initial progress followed by a significant shedding phase. Others in the conversation reassured that shedding is normal and suggested staying consistent with the treatment for potential regrowth.

The user has been using a topical solution containing minoxidil and finasteride for 10 months but is not satisfied with the results, as there is no significant hair regrowth or thickening. They are questioning whether they are a non-responder or if they should continue the treatment longer.

After stopping finasteride, the user retained hair without noticeable balding, suggesting an unusual reaction to the medication. The user initially experienced rapid hair loss and itchiness, possibly due to male pattern baldness, but maintained hair stability after tapering off finasteride.

User shared 2-year finasteride results, showing maintenance without regrowth or further recession. Experienced ball ache for a month, but no other side effects.

The user observed some regrowth and longer baby hairs after one month of using finasteride, despite experiencing increased shedding. They noted no side effects except for clear semen.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

The conversation is about a user experiencing positive results with finasteride for hair loss after three months, with no side effects and increased libido. Other users discuss their experiences, suggest adding minoxidil, and inquire about dosage and side effects.

The user was using 1mg finasteride daily and oral minoxidil 2.5mg daily for two years, then added RU58841 to their routine two months ago and is asking for opinions on any changes in hair growth. They provided progress pictures without dermarolling and maintained consistent lighting for comparison.

The user is experiencing hair regrowth after 4.5 months of using oral minoxidil, oral dutasteride, latanoprost, ketoconazole shampoo, and dermarolling. They report shedding initially but have seen improvement without significant side effects.

The conversation is about someone sharing their 2.5-year hair regrowth journey using finasteride and topical minoxidil, emphasizing the importance of consistency and patience with these treatments. They also mention using tea tree conditioner and experiencing no side effects from oral finasteride.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The user noticed hair improvement after using 1mg finasteride for 1 year and 3mg minoxidil for 3 months. Others shared similar experiences, noting stability or slight progress in hair regrowth.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

The user shared progress pictures after 4 months of using 1.25 mg oral Finasteride every other day. Responses indicate hair regrowth and a filling hairline, with one user asking about side effects or shedding.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

The user experienced a severe hair shedding phase after switching to a combination pill of finasteride, minoxidil, and B12, but the shedding has now significantly reduced. Other users shared similar experiences, noting that shedding can be a sign of treatment effectiveness.

The user is experiencing severe hair shedding after using RU58841, stemoxydine, and minoxidil, and has stopped using finasteride due to side effects. They hope the shedding is temporary and will lead to regrowth.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The user is sharing their experience with using 0.5mg dutasteride, 2.5mg oral minoxidil, and hair dye for 45 days. Another user encourages them to continue as it is still too early to see significant improvement.

A user experienced increased testosterone and estradiol levels after starting finasteride/dutasteride and is asking if these levels will return to normal over time. The conversation focuses on whether these changes are temporary.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The user experienced regrowth and stabilization in hair density using finasteride, minoxidil, a derma roller, and an LLLT helmet, but noticed a recent decline in hair quality. They only take finasteride orally and are unsure about the effectiveness of the LLLT device.

The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The user experienced significant hair regrowth after using oral and topical minoxidil and finasteride for over three months. They reported minimal side effects, such as facial hair growth and minor bloating, and are optimistic about continued progress.